Everolimus With Reduced Exposure to a Calcineurin Inhibitor in Pediatric Liver Transplant Recipients: Baseline Data From the H2305 Study.

被引：0
|
作者：
Ganschow, R. [1 ]
Fischer, L. [1 ]
Ericzon, B. [1 ]
Dhawan, A. [1 ]
D'Alessandro, A. [1 ]
Goss, J. [1 ]
Sips, C. [1 ]
Balfour, A. [1 ]
Junge, G. [1 ]
机构：
[1] H2305 Study Grp, Hamburg, Germany
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2014年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B1060
引用
收藏
页码：719 / 719
页数：1
相关论文
共 50 条
  • [41] Everolimus Plus Reduced-Exposure Calcineurin Inhibitor Versus Mycophenolate Mofetil Plus Standard-Exposure Calcineurin Inhibitor: 2-Year Results in Living Donor Kidney Transplant Recipients
    Watarai, Y.
    Akutsu, N.
    Saito, K.
    Nakagawa, Y.
    Kamisawa, O.
    Kenmochi, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [42] The TRANSFORM Study: Infection Outcomes with Everolimus Plus Reduced Calcineurin Inhibitor and Mycophenolate Plus Standard Calcineurin Inhibitor Regimens in De Novo Kidney Transplant Recipients.
    Vincenti, F.
    Cruzado, J.
    Mulgaonkar, S.
    Garcia, V.
    Kuypers, D.
    Buchler, M.
    Citterio, F.
    Huynh-Do, U.
    Luo, W-L.
    Bernhardt, P.
    Sommerer, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 258 - 258
  • [43] THE TRANSFORM STUDY: 12-MONTH EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS
    Pascual, Julio
    Berger, Stefan
    Witzke, Oliver
    Chadban, Steve
    Oppenheimer, Federico
    Oberbauer, Rainer
    Watarai, Yoshihiko
    Legendre, Christophe
    Luo, Wen-Lin
    Marti, Anamaria
    Bernhardt, Peter
    Tedesco, Helio
    TRANSPLANT INTERNATIONAL, 2017, 30 : 159 - 159
  • [44] LIPID ABNORMALITIES AND CARDIOVASCULAR EVENTS IN RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR REGIMEN: 24-MONTH ANALYSIS FROM TRANSFORM STUDY
    Sommerer, Claudia
    Legendre, Christophe
    Citterio, Franco
    Watarai, Yoshihiko
    Oberbauer, Rainer
    Basic-Jukic, Nikolina
    Garcia, Valter Duro
    Peddi, V. Ram
    Hernandez-Gutierrez, Maria-Pilar
    Narvekar, Prachiti
    Bernhardt, Peter
    Chadban, Steve
    TRANSPLANT INTERNATIONAL, 2019, 32 : 71 - 71
  • [45] Progression of liver fibrosis in HCV-positive liver transplant recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) therapy or a standard CNI regimen
    Saliba, Faouzi
    Nevens, Frederik
    TRANSPLANT INTERNATIONAL, 2015, 28 (03) : 373 - 374
  • [46] THE TRANSFORM STUDY: EFFECT OF EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR ON 12-MONTH RENAL FUNCTION OUTCOMES IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS
    Oppenheimer, Federico
    Witzke, Oliver
    Viklicky, Ondrej
    Cassuto, Elisabeth
    De Fijter, Johan
    Huynh-Do, Uyen
    Russ, Graeme
    Srinivas, Titte
    Luo, Wen-Lin
    Bernhardt, Peter
    Qazi, Yasir
    TRANSPLANT INTERNATIONAL, 2017, 30 : 162 - 162
  • [47] Effect of Induction Therapy on Outcomes of De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from the TRANSFORM Study.
    Oberbauer, R.
    Vincenti, F.
    Viklicky, O.
    Huynh-Do, U.
    Kim, D.
    Cruzado, J. M.
    Qazi, Y.
    Kim, M. S.
    Narvekar, P.
    Gutierrez, M. P. Hernandez
    Bernhardt, P.
    Kuypers, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 558 - 558
  • [48] Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients
    Manzia, T. M.
    Angelico, R.
    Toti, L.
    Grimaldi, C.
    Sforza, D.
    Vella, I.
    Tariciotti, L.
    Lenci, I.
    Breshanaj, G.
    Baiocchi, L.
    Tisone, G.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (01) : 175 - 183
  • [49] Calcineurin inhibitor-free immunosuppressive protocol with basiliximab induction and everolimus in de novo liver transplant recipients
    Masetti, Michele
    Montalti, Roberto
    Rompianesi, Gianluca
    Romano, Antonio
    Guerrini, Gianpiero
    De Ruvo, Nicola
    Gerunda, Giorgio E.
    TRANSPLANT INTERNATIONAL, 2007, 20 : 124 - 125
  • [50] Exposure-Response Analysis of Everolimus and Tacrolimus in De Novo Liver Transplant Recipients: 24-Month Results from the H2304 Study.
    Fischer, L.
    Kaiser, G. M.
    Huang, M. A.
    Toselli, L.
    Durand, F.
    Heaton, N.
    Shetty, K.
    Klintmalm, G.
    Dong, G.
    Lopez, P.
    Junge, G.
    Kovarik, J. M.
    LIVER TRANSPLANTATION, 2013, 19 : S148 - S148
12345